Wikipedia -WSS

Wikipedia

author：leisure time 2025-10-02 20:47:11 - browse：693

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Verily hires former Apple Health leader as chief scientific officer

hotspot

leisure time

WSS

Verily hires former Apple Health leader as chief scientific officer

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

Grail faces three suits alleging harassment, retaliation

J&J expands global access to TB drug amid advocacy campaign

TytoCare raises $49 million to build out AI

Congress likely to miss an opportunity to fix drug shortages issue

leisure time

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Virginia high school admissions case could be legal follow

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

Guidelines to prevent youth baseball injuries need more muscle

Care demand spikes challenge UnitedHealth’s provider arm

Continuity nursing helped my family in our darkest PICU moments

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

What does generative AI mean for health care? We asked experts

Dramatically reducing cancer deaths requires the PASTEUR Act

hotspot

2 US Navy sailors arrested for allegedly spying for China

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

Biden calls for immediate release of Niger's president amid apparent coup

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

hotspot

Wikipedia

leisure time

explore